MYSELF

DR ANTHONY MELVIN CRASTO Ph.D ( ICT, Mumbai) , INDIA 36Yrs Exp. in the feld of Organic Chemistry,Working for AFRICURE PHARMA as ADVISOR earlier with GLENMARK PHARMA at Navi Mumbai, INDIA. Serving chemists around the world. Helping them with websites on Chemistry.Million hits on google, NO ADVERTISEMENTS , ACADEMIC , NON COMMERCIAL SITE, world acclamation from industry, academia, drug authorities for websites, blogs and educational contribution, ........amcrasto@gmail.com..........+91 9323115463, Skype amcrasto64

DR ANTHONY MELVIN CRASTO Ph.D

DR ANTHONY MELVIN CRASTO, Born in Mumbai in 1964 and graduated from Mumbai University, Completed his Ph.D from ICT, 1991,Matunga, Mumbai, India, in Organic Chemistry, The thesis topic was Synthesis of Novel Pyrethroid Analogues, Currently he is working with AFRICURE PHARMA, ROW2TECH, NIPER-G, Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Govt. of India as ADVISOR, earlier assignment was with GLENMARK LIFE SCIENCES LTD, as CONSUlTANT, Retired from GLENMARK in Jan2022 Research Centre as Principal Scientist, Process Research (bulk actives) at Mahape, Navi Mumbai, India. Total Industry exp 32 plus yrs, Prior to joining Glenmark, he has worked with major multinationals like Hoechst Marion Roussel, now Sanofi, Searle India Ltd, now RPG lifesciences, etc. He has worked with notable scientists like Dr K Nagarajan, Dr Ralph Stapel, Prof S Seshadri, etc, He did custom synthesis for major multinationals in his career like BASF, Novartis, Sanofi, etc., He has worked in Discovery, Natural products, Bulk drugs, Generics, Intermediates, Fine chemicals, Neutraceuticals, GMP, Scaleups, etc, he is now helping millions, has 9 million plus hits on Google on all Organic chemistry websites. His friends call him Open superstar worlddrugtracker. His New Drug Approvals, Green Chemistry International, All about drugs, Eurekamoments, Organic spectroscopy international, etc in organic chemistry are some most read blogs He has hands on experience in initiation and developing novel routes for drug molecules and implementation them on commercial scale over a 32 PLUS year tenure till date Feb 2023, Around 35 plus products in his career. He has good knowledge of IPM, GMP, Regulatory aspects, he has several International patents published worldwide . He has good proficiency in Technology transfer, Spectroscopy, Stereochemistry, Synthesis, Polymorphism etc., He suffered a paralytic stroke/ Acute Transverse mylitis in Dec 2007 and is 90 %Paralysed, He is bound to a wheelchair, this seems to have injected feul in him to help chemists all around the world, he is more active than before and is pushing boundaries, He has 100 million plus hits on Google, 2.5 lakh plus connections on all networking sites, 100 Lakh plus views on dozen plus blogs, 227 countries, 7 continents, He makes himself available to all, contact him on +91 9323115463, email amcrasto@gmail.com, Twitter, @amcrasto , He lives and will die for his family, 90% paralysis cannot kill his soul., Notably he has 38 lakh plus views on New Drug Approvals Blog in 227 countries......https://newdrugapprovals.wordpress.com/ , He appreciates the help he gets from one and all, Friends, Family, Glenmark, Readers, Wellwishers, Doctors, Drug authorities, His Contacts, Physiotherapist, etc He has total of 32 International and Indian awards

Verified Services

View Full Profile →

Access 4,000+ profiles of new drugs in development!

September 6, 2013 3:37 am / 4 Comments on Access 4,000+ profiles of new drugs in development!

Sign up for a 5-day trial and learn why the Drugs in Clinical Trials Database is a cost-effective way to find detailed information on new drug therapies in hundreds of disease conditions worldwide, monitor drug performance, track competitors and find study opportunities.

http://www.centerwatch.com/drug-information/demo/?utm_source=DDD&utm_medium=web&utm_campaign=DDBSept2013&pos=2&adtype=text_ad&type=image&adcategory=paid

FDA Accepts Endo’s Aveed Application

September 6, 2013 3:25 am / 3 Comments on FDA Accepts Endo’s Aveed Application

Endo Health Solutions said that regulators accepted for review new data for its long-acting testosterone injection Aveed and will make a ruling on the drug by Feb. 28. The Food and Drug Administration asked Endo for more information in May.

http://www.dddmag.com/news/2013/09/fda-accepts-endos-aveed-application?et_cid=3463690&et_rid=523035093&type=headline

FULL STORY

Niche play, alliances hold promise for Biocon

September 5, 2013 5:10 am / 6 Comments on Niche play, alliances hold promise for Biocon

DR KIRAN SHAW MAXUMDAR

MD BIOCON

Niche play, alliances hold promise for Biocon

While biosimilar opportunity in the regulated markets is likely to play out in the medium term, its existing biopharma and branded portfolio will ensure growth in the short term

Niche play, alliances hold promise for Biocon
Business Standard
Innovator sales for these two drugs are pegged at $10 billion which is slightly over half of the worldwide insulin market of $19 billion.On the monoclonal antibody front, the company is in phase III for the cancer drug Trastuzumab which has a market …

READ ALL THIS AT

http://www.business-standard.com/article/companies/niche-play-alliances-hold-promise-for-biocon-113090500095_1.html

HIV/AIDS vaccine passes Phase 1 clinical trial in humans

September 5, 2013 5:04 am / 3 Comments on HIV/AIDS vaccine passes Phase 1 clinical trial in humans

HIV/AIDS vaccine passes Phase 1 clinical trial in humans
DVICE
While other HIV/AIDS vaccines that haven’t used killed whole viruses (relying instead on targeting specific components of HIV) have failed in Phase 3 trials, Sumagen is optimistic about their drug because other successful vaccines (including polio …read all at

http://www.dvice.com/2013-9-4/hivaids-vaccine-passes-phase-1-clinical-trial-humans

European Approval for Glaxos Tafinlar

September 5, 2013 5:02 am / 3 Comments on European Approval for Glaxos Tafinlar

European Approval for Glaxos Tafinlar

Zacks.com

GlaxoSmithKline (GSK – Analyst Report) recently announced that its melanoma drug, Tafinlar, has been cleared by the European Commission (EC). Tafinlar is indicated as a monotherapy for treating adults suffering from unresectable or metastatic melanoma with a BRAF V600 mutation

The approval came on the basis of encouraging data from several multi-center global trials including the phase III BREAK-3 study. We remind investors that … Currently approved melanoma drugs include Zelboraf and Yervoy. Glaxo carries a Zacks Rank #3 …http://www.zacks.com/stock/news/108341/european-approval-for-glaxos-tafinlar

Cytokinetics: Clinical Investigators’ Opinions On ATOMIC-AHF Trial Results

September 5, 2013 4:54 am / 2 Comments on Cytokinetics: Clinical Investigators’ Opinions On ATOMIC-AHF Trial Results

omecamtiv mecarbil

Cytokinetics, Inc. (CYTK): Cytokinetics: Clinical Investigators’ Opinions On …
Seeking Alpha
Pending the results of the ongoing COSMIC-HF trial in 1H, 2014, I believe that the ATOMIC-AHF results support moving omecamtiv mecarbil into Phase III. With success in the Phase III, omecamtiv mecarbil would likely be a several billion drug. I regard …http://seekingalpha.com/article/1672892-cytokinetics-clinical-investigators-opinions-on-atomic-ahf-trial-results?source=google_news

Omecamtiv mecarbil (INN), previously codenamed CK-1827452, is a cardiac specific myosin activator. It is clinically tested for its role in the treatment of left ventricular systolic heart failure.^[1] Systolic heart failure is characterised as a decreased cardiac output (<40% ejection fraction), due to decreased stroke volume, resulting in the inability to meet the metabolic demands of the body.^[2] The loss of contraction is caused by a reduced number of effective actin-myosin cross bridges in the left ventricular myocytes. One possible underlying mechanism is altered signal transduction that interferes with excitation-contraction coupling.^[3] A decreased cardiac output causes peripheral hypotension and activation of the sympathetic nervous system.^[2] This in turn stimulates the cardiac myocytes excessively, eventually leading to left ventricular hypertrophy, characteristic of chronic heart failure. Some symptoms of systolic heart failure are fatigue, peripheral oedema, dyspnoea, exercise intolerance and breathlessness.^[2] Current inotropic drug therapies such as dobutamine, are palliative and not a cure. They also cause many adverse effects including arrhythmias related to increased myocardical oxygen consumption, desensitization of adrenergic receptors and altering intracellular calcium levels.^[4] Thus systolic heart failure is considered malignant, however the novel mechanism of Omecamtiv Mecarbil is a hopeful long-term resolution.

Mechanism of action

Cardiac myocytes contract through a cross-bridge cycle between the myofilaments, actin and myosin. Chemical energy in the form of ATP is converted into mechanical energy which allows myosin to strongly bind to actin and produce a power stroke resulting in sarcomere shortening/contraction.^[3] Omecamtiv Mecarbil specifically targets and activates myocardial ATPase and improves energy utilization. This enhances effective myosin cross-bridge formation and duration, while the velocity of contraction remains the same.^[5] It also increases the rate of phosphate release from myosin, thereby accelerating the rate-determining step of the cross-bridge cycle, which is the transition of the actin-myosin complex from the weakly bound to the strongly bound state.^[1] The overall result of Omecamtiv Mecarbil is an increase in left ventricular systolic ejection time, sarcomere shortening and stroke volume, while the systolic pressure remains the same.^[5] This causes a decrease in heart rate while myocardial oxygen consumption is unaffected. The increased cardiac output is independent of intracellular calcium and cAMP levels.^[4]^[6] Thus Omecamtiv Mecarbil improves systolic function by increasing the systolic ejection duration/stroke volume, without consuming more ATP energy, oxygen or altering intracellular calcium levels causing an overall improvement in cardiac efficiency.^[5]

Clinical trials

Experimental studies on rats and dogs, proved the efficacy and mechanism of action of Omecamtiv Mecarbil.^[4] Current clinical studies on humans have shown there is a direct linear relationship between dose and systolic ejection time.^[1]^[7]^[8] The dose-dependent effects persisted throughout the entire trial, suggesting that desensitization does not occur. The maximum tolerated dose was observed to be an infusion of 0.5 mg/kg/h. Adverse effects, such as ischemia, were only seen at doses beyond this level, due to extreme lengthening of systolic ejection time.^[1] Thus due to the unique cardiac myosin activation mechanism, Omecamtiv Mecarbil could safely improve cardiac function within tolerated doses. Omecamtiv Mecarbil effectively relieves symptoms and enhances the quality of life of systolic heart failure patients. It drastically improves cardiac performance in the short term, however the hopeful long term effects of reduced mortality have yet to be studied.^[2]^[1]

^ ^a ^b ^c ^d ^e Teerlink, JR (2009). “A novel approach to improve cardiac performance: cardiac myosin activators”. Heart Fail Rev 14 (4): 289–298. doi:10.1007/s10741-009-9135-0. ISSN 1382-4147.
^ ^a ^b ^c ^d Dyke D, Koelling T (2008). “Heart failure due to left ventricular systolic dysfunction”. In Eagle KA, Baliga RR. Practical Cardiology. Philadelphia: Lippincott Williams & Wilkins. pp. 246–285. ISBN 978-0-7817-7294-5.
^ ^a ^b Bers, DM (Jan 2002). “Cardiac excitation-contraction coupling”. Nature 415 (6868): 198–205. doi:10.1038/415198a. PMID 11805843.
^ ^a ^b ^c Shen YT, Malik FI, Zhao X, Depre C, Dhar SK, Abarzúa P, Morgans DJ, Vatner SF (Jul 2010). “Improvement of cardiac function by a cardiac myosin activator in conscious dogs with systolic heart failure”. Circ Heart Fail 3 (4): 522–7. doi:10.1161/CIRCHEARTFAILURE.109.930321. PMID 20498236.
^ ^a ^b ^c Malik F, Teerlink J, Escandon R, Clake C, Wolff A (2006). “The Selective Cardiac Myosin Activator, CK-1827452, a Calcium-Independent Inotrope, Increases Left Ventricular Systolic Function by Increasing Ejection Time Rather than the Velocity of Contraction”. Circulation 114 (18 Suppl): 441.
^ Teerlink JR, Metra M, Zacà V, Sabbah HN, Cotter G, Gheorghiade M, Cas LD (Dec 2009). “Agents with inotropic properties for the management of acute heart failure syndromes. Traditional agents and beyond”. Heart Fail Rev 14 (4): 243–53. doi:10.1007/s10741-009-9153-y. PMID 19876734.
^ Teerlink JR, Clarke CP, Saikali KG, Lee JH, Chen MM, Escandon RD, Elliott L, Bee R, Habibzadeh MR, Goldman JH, Schiller NB, Malik FI, Wolff AA (Aug 2011). “Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study.”. Lancet 378 (9792): 667–75. doi:10.1016/S0140-6736(11)61219-1. PMID 21856480.
^ Cleland JG, Teerlink JR, Senior R, Nifontov EM, Mc Murray JJ, Lang CC, Tsyrlin VA, Greenberg BH, Mayet J, Francis DP, Shaburishvili T, Monaghan M, Saltzberg M, Neyses L, Wasserman SM, Lee JH, Saikali KG, Clarke CP, Goldman JH, Wolff AA, Malik FI (Aug 2011). “The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial”. Lancet 378 (9792): 676–83. doi:10.1016/S0140-6736(11)61126-4. PMID 21856481.

Welcome to Bioinfomedical.com

September 5, 2013 4:31 am / 2 Comments on Welcome to Bioinfomedical.com

http://www.bioinfomedical.com/index.php

Prof. Dr. Rafael Boritzer

P.O.Box 88355, Honolulu, Hawaii 96830 U.S.A.

boritzer@bioinfomedical.com

http://www.bioinfomedical.com/index.php

we are marketers of non-branded recombinant proteins with a primary mission of high quality, low priced material for encouraging biopharma research and development outside of North America. We try to integrate our supply services with education of our clients’ with industry videos and information.

Welcome to Bioinfomedical.com

BioInfoMedical was established in 1989 by a team of experienced medical specialists, world-known scientists and marketing professionals. The company has two operating divisions:

InfoMedical Biotechnology and InfoMedical Consulting.

InfoMedical Biotechnology provides products and services used in gene, protein and cell research, drug discovery and development, as well as in biopharmaceutical manufacturing.

InfoMedical Consulting assists companies in strategic market expansion, industry research, environmental analysis, and developing successful market plans for worldwide business-winners.

We are proud to serve our customers around the globe. Our clients are: academic research institutions, biotechnology and pharmaceutical companies, medical research centers, hospitals, reference laboratories, agricultural and chemical companies, as well as leading private and governmental business organizations.

…………………………………………………………………………………………………….

see a video of DR RAFI

………………………………………………………………………………………………………….

Cytokines

Growth Factors

Chemokines

CD Antigens

CD Antigens

Neurotrophins

Hormones

Enzymes

Viral Antigens

Recombinant Proteins

Natural Proteins

Monoclonal Antibodies

Polyclonal Antibodies

Test Category New

http://www.bioinfomedical.com/index.php

Diet Pill Dilemma: Why Is FDA Approving Drugs When Europe Isn’t?

September 4, 2013 12:14 pm / 1 Comment on Diet Pill Dilemma: Why Is FDA Approving Drugs When Europe Isn’t?

We’ve all dreamt of popping a pill to help us safely lose weight, or at least eat that chocolate cake without guilt. But alas, even though the Food and Drug Administration has approved two new diet drugs in recent months, that dream probably isn’t any closer to reality.

In the current issue of the BMJ (formerly the British Medical Journal), Sidney Wolfe, founder of the advocacy group Public Citizen, slams the FDA for approving the drugs – lorcaserin (US brand name Belviq) and topiramate (called Qsymia). The FDA’s European counterpart rejected both of them because of heart risks that turned up during preliminary trials.

read all this at

http://commonhealth.wbur.org/2013/08/diet-pill-dilemma-why-is-fda-approving-drugs-when-europe-isnt

A Return to Health

September 4, 2013 12:01 pm / Leave a comment

Yoga in India

One Woman’s Ayurvedic Experience

by Jodi Boone

Over a cup of tea, she told me how they found her tumour. Mira, a middle-aged woman with large blue eyes and a gentle smile, holds a Ph.D. in Organizational Development and works as an administrator for the Swedish Army.

She explained how the stress and long hours of her work had culminated in 25 kilos of extra weight and high blood pressure. “For 20 years, I didn’t have time for myself – no time for exercise and no energy to shop or cook meals at home,” Mira said. Devoted to her studies in her 20’s and later to her career, Mira acknowledged that her trip to India in 2010 was the first time in her life she’d taken to focus on her health.

“I’d never been to India before, and I’d never heard of Ayurveda,” said Mira. One evening, as she searched…

View original post 955 more words

Fruit Lowers the Risk of Diabetes

September 4, 2013 11:57 am / Leave a comment

Medical Revolt

The press is all over a recent study done at the Harvard school of public health that was published in the British Medical Journal last week. The study showed that those that ate fruit had a lower risk of diabetes. Specifically they singled out blueberries for a 25% reduction in risk. Grapes offered 11%, apples 5%, prunes 11%, pears 7%. This was not a randomized trial so there are a lot of uncontrolled variables but that being said they did look at 187,382 patients so that sample size does give this study a lot of weight. It also brings further support to a recommendation I have been giving to my diabetic or pre-diabetic patients for years, become a vegan and forget about the ADA (American Diabetes Association) diet.

A study done in 2006 published in Diabetes Care compared patients on a Vegan diet to patients on the ADA diet. The Vegan diet patients…

View original post 311 more words

Latest Posts

Andamertinib
Andamertinib CAS 2254145-43-0 MF C31H36N8O3 MW568.7 g/mol N-[4-methoxy-2-[4-(3-methoxyazetidin-1-yl)piperidin-1-yl]-5-[[6-(1-methylindazol-5-yl)pyrimidin-4-yl]amino]phenyl]prop-2-enamide N-(4-methoxy-2-[4-(3-methoxyazetidin-1-yl)piperidin-1-yl]-5-{[6-(1-methyl-1H-indazol-5-yl)pyrimidin-4-yl]amino}phenyl)prop-2-enamideepidermal growth factor receptor tyrosine kinase inhibitor, antineoplastic, PLB 1004, 5X3KAG7ZBW Andamertinib (also known as PLB1004) is an investigational, orally…
Amsulostat
Amsulostat CAS 2409963-83-1 MF C13H13FN2O2S MW280.32 2-Buten-1-amine, 3-fluoro-4-(8-quinolinylsulfonyl)-, (2Z)- (2Z)-3-fluoro-4-(quinolin-8-ylsulfonyl)but-2-en-1-amine (Z)-3-fluoro-4-quinolin-8-ylsulfonylbut-2-en-1-amine (2Z)-3-fluoro-4-(quinolin-8-ylsulfonyl)but-2-en-1-amineprotein-lysine-oxidase (LOX) inhibitor, antifibrotic, PXS 5505, LOX inhibitor PXS-5505, LOX-IN-3, pan-LOX inhibitor PXS-5505, DO94E28WYW,…
Amezalpat
Amezalpat CAS 1616372-41-8 MF C34H41N3O4 MW555.7 g/mol 2-[5-[3-[3-[1-[(4-tert-butylphenyl)methyl]-4-ethyl-5-oxo-1,2,4-triazol-3-yl]propyl]phenyl]-2-ethoxyphenyl]acetic acid peroxisome proliferator-activated receptor alpha (PPARα) antagonist, antineoplastic, TPST 1120, FDA Fast Track, Orphan Drug, 1EQ4LQN9N3 Amezalpat (formerly…
Alnodesertib
Alnodesertib CAS 2267316-76-5 MF C18H24N6O2S MW388.49 4-[4-[(cyclopropyl-methyl-oxo-λ6-sulfanylidene)amino]-6-[(3R)-3-methylmorpholin-4-yl]pyrimidin-2-yl]pyridin-2-amine 4-[4-[(cyclopropyl-methyl-oxo-lambda6-sulfanylidene)amino]-6-[(3R)-3-methylmorpholin-4-yl]pyrimidin-2-yl]pyridin-2-amine (S)-({2-(2-aminopyridin-4-yl)-6-[(3R)-3-methylmorpholin-4-yl]pyrimidin-4-yl}imino)(cyclopropyl)(methyl)-λ6-sulfanoneserine/threonine kinase inhibitor, antineoplastic, ART 0380, EX-A9085 Alnodesertib (formerly known as ART0380) is an investigational, orally administered drug designed to…
Alixorexton
Alixorexton CAS 2648347-56-0 MF C21H30N2O5S MW 422.5 g/mol N-((21S,24S,52R,53S)-6-oxo-3,8-dioxa-5(2,1)-piperidina-1(1,2)-benzena-2(1,4)-cyclohexanacyclooctaphane-53-yl)methanesulfonamide N-[(15S,16R)-10-oxo-8,18-dioxa-11-azatetracyclo[17.2.2.02,7.011,16]tricosa-2,4,6-trien-15-yl]methanesulfonamide N-[7,10-cis-(4S,4aR)-17-oxo-1,2,3,4,4a,5,7,8,9,10,16,17-dodecahydro-7,10-ethanopyrido[1,2-d][1,7,4]benzodioxaazacyclotridecin-4-yl]methanesulfonamideorexin-2 receptor agonist, ALKS 2680, Breakthrough Therapy designation, 3BRW4ARU66, TAK 994, firazorexton Alixorexton (formerly ALKS 2680)…
Zeprumetostat
Zeprumetostat CAS 2098545-98-1 MF C32H44N4O4 MW 548.7 g/mol CHINA 2025, APPROVALS 2025 N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-5-ethyl-6-[ethyl(oxan-4-yl)amino]-2-(piperidin-1-ylmethyl)-1-benzofuran-4-carboxamide N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-5-ethyl-6-[ethyl(oxan-4-yl)amino]-2-[(piperidin-1-yl)methyl]-1-benzofuran-4-carboxamideenhancer of zeste homolog 2 (EZH2) inhibitor, antineoplastic, Airijing® (China), EZH2-IN-15, SHR 2554…
Zelebrudomide
Zelebrudomide CAS 2416131-46-7 MF C39H45N9O5 MW 719.8 g/mol 3-[4-[1-[[(3S)-1-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl]pyrrolidin-3-yl]methyl]piperidin-4-yl]anilino]-5-piperidin-1-ylpyrazine-2-carboxamide 3-[[4-[1-[[(3S)-1-[2-(2,6-Dioxo-3-piperidyl)-1,3-dioxo-5-isoindolinyl]-3-pyrrolidinyl]methyl]-4-piperidyl]phenyl]amino]-5-(1-piperidyl)pyrazine-2-carboxamide protein degrader, antineoplastic, NX 2127, LSC67HA8DE, NX-2127, BTK Degrader NX-2127 Zelebrudomide (NX-2127) is an investigational new drug that is…
Zanvipixant
Zanvipixant CAS 2166558-11-6 MF C17H12F5N7O MW 425.3 g/mol [(6S)-1-(5-fluoropyrimidin-2-yl)-6-methyl-6,7-dihydro-4H-triazolo[4,5-c]pyridin-5-yl]-[3-fluoro-2-(trifluoromethyl)-4-pyridinyl]methanone METHANONE, ((6S)-1-(5-FLUORO-2-PYRIMIDINYL)-1,4,6,7-TETRAHYDRO-6-METHYL-5H-1,2,3-TRIAZOLO(4,5-C)PYRIDIN-5-YL)(3-FLUORO-2-(TRIFLUOROMETHYL)-4-PYRIDINYL)- [(6S)-1-(5-fluoropyrimidin-2-yl)-6-methyl-1,4,6,7-tetrahydro-5H-[1,2,3]triazolo[4,5-c]pyridin-5-yl][3-fluoro-2-(trifluoromethyl)pyridin-4-yl]methanonepurinoreceptor (P2X) antagonist, JNJ-55308942, JNJ 55308942, B7YN3CQ7S7, JNJ-55308942 is under investigation in clinical trial NCT05328297…
Vormatrigine
Vormatrigine CAS 2392951-18-5 MF C16H12F6N4O2 MW406.28 g/mol 3-(ethoxydifluoromethyl)-6-(5-fluoro-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine 3-[ethoxydi(fluoro)methyl]-6-[5-fluoro-6-(2,2,2-trifluoroethoxy)pyridin-3-yl][1,2,4]triazolo[4,3-a]pyridinesodium channel blocker, PRAX-628, PRAX 628, QU3C48T4NV, Vormatrigine is a small molecule drug. The usage of the INN…
Veonetinib
Veonetinib 👉CAS 1210828-09-3 MF C27H28FN3O4 MW 477.5 g/mol 5-[2-[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxyquinolin-7-yl]oxyethyl]-5-azaspiro[2.4]heptan-7-ol 5-AZASPIRO(2.4)HEPTAN-7-OL, 5-(2-((4-((4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY)-6-METHOXY-7-QUINOLINYL)OXY)ETHYL)- 5-(2-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)ethyl)-5-azaspiro[2.4]-heptan-7-ol (7RS)-5-[2-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxyquinolin7-yl}oxy)ethyl]-5-azaspiro[2.4]heptan-7-oltyrosine kinase inhibitor, antineoplastic, U7PA8S6XGJ 👉SYN [WO2010021918] Example 3 5-(2-(4-(4-fluoro-2-methyl-lH-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)ethyl)-5-azaspiro[2.4]-heptan-7-ol The above product from…

DISCLAIMER

I , Dr A.M.Crasto is writing this blog to share the knowledge/views, after reading Scientific Journals/Articles/News Articles/Wikipedia. My views/comments are based on the results /conclusions by the authors(researchers). I do mention either the link or reference of the article(s) in my blog and hope those interested can read for details. I am briefly summarising the remarks or conclusions of the authors (researchers). If one believe that their intellectual property right /copyright is infringed by any content on this blog, please contact or leave message at below email address amcrasto@gmail.com. It will be removed ASAP

Blog at WordPress.com.

	shivkr2 on SPSR Excellence Award 2025 – S…
	Bonkasaurus on Infigratinib phosphate
	PALOVAROTENE \| ORGAN… on Palovarotene
	Pfizer just purchase… on Temanogrel
	Pfizer To Cash In On… on Temanogrel
	VÍDEOS – A Pfizer ac… on Temanogrel
	Pfizer Bought Arena… on Temanogrel
	Pfizer va profita de… on Temanogrel
	Pfizer to Cash In on… on Temanogrel
	Pfizer tocmai a achi… on Temanogrel
	Pfizer just purchase… on Temanogrel
	Pfizer just purchase… on Temanogrel
	Tanya A on Dasotraline, ダソトラリン
	Julia Chernus on RIDINILAZOLE
	Adv.Siji Antony Kera… on Myself Anthony Crasto up for g…

SEARCH THIS BLOG

FLAGS AND HITS

Meta

Pages

Archives

Categories

MYSELF

Follow Blog via Email

Verified Services

Recent Posts

SEARCH THIS BLOG

Share this:

Share this:

Niche play, alliances hold promise for Biocon

Share this:

Share this:

Share this:

Mechanism of action

Clinical trials

Share this:

Share this:

Share this:

Share this:

Share this:

Post navigation

SEARCH THIS BLOG

DR ANTHONY MELVIN CRASTO

Meta

Follow Blog via Email

ORGANIC SPECTROSCOPY

Latest Posts

Pages

feedjit

Recent Comments

DISCLAIMER

SEARCH THIS BLOG

SEARCH THIS BLOG

FLAGS AND HITS

Follow Blog via Email